ION ETF

Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design Bayley-4 expressive communication selected as Phase 3 study primary endpoint Initiation of ION582 Phase 3 study planned for H1 2025 Ionis to share ION582 program update at the FAST Global Science Summit in November CARLSBAD, Calif. , Nov. 6, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pivotal Phase 3 study design following successful alignment with the U.S. Food and Drug Administration (FDA) on ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS).

Romaine Jackson of ION Analytics cites tailwinds in India positioning it as an attractive market for South Korea's chaebols to enter.

CAH is set to acquire Oncology Network for $1.115 billion, expanding its oncology offerings while supporting community-based cancer care across 10 states.

CINCINNATI , Sept. 19, 2024 /PRNewswire/ -- Average viewership for the State Farm WNBA Friday Night Spotlight on ION in 2024 increased by 133% from 2023, and the network attracted 23.37 million unique viewers across games and wrap shows.